Cardiovasoactive Peptides in Hemodialysis Patients: Diagnostic Tools and Predictors of Outcome: A Review of Present Knowledge and Future Directions
| Autor: | C. M. Kjellstrand, Ingegerd Odar-Cederlöf |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
medicine.medical_specialty
Sympathetic nervous system business.industry medicine.medical_treatment Volume overload Hematology Calcitonin gene-related peptide Brain natriuretic peptide medicine.disease medicine.anatomical_structure Atrial natriuretic peptide Nephrology Heart failure Internal medicine medicine Cardiology Hemodialysis Intensive care medicine business Dialysis |
| Zdroj: | Hemodialysis International. 7:222-231 |
| ISSN: | 1492-7535 |
| DOI: | 10.1046/j.1492-7535.2003.00042.x |
| Popis: | The main cardiovasoactive peptides involved in cardiovascular adaptation to renal failure and dialysis are reviewed with a special focus on their possible role in pathophysiology, diagnosis of cardiovascular and fluid volume abnormalities, and prognostic information. The role of vasoactive peptides in cardiovascular stability during hemodialysis (HD) are best seen in sequential HD, where the release of vasoconstrictors is stimulated by volume reduction during ultrafiltration, but is blunted during isovolemic HD, whereas plasma vasodilators increase. Plasma levels of the natriuretic peptides atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are elevated in fluid volume overload and heart failure and decrease during dialysis. Neuropeptide Y (NPY) is elevated in severe volume overload and hypertension and calcitonin gene-related peptide in large-volume overload. Plasma BNP increases with left ventricular failure and improves during dialysis. Activation of the sympathetic nervous system as reflected by increased plasma levels of NPY is associated with poor prognosis. High levels of the natriuretic peptides ANP and BNP are likewise predictors of poor prognosis. Determinations of plasma levels of cardiovasoactive peptides may be helpful in clinical practice to diagnose volume overload and heart failure and to assess the severity of heart failure and of hypertension, as a guide to the choice of dialysis treatment and pharmacotherapy and to monitor treatment. Clinical studies will be needed in HD patients to establish the value of measurement of plasma cardiovasoactive peptides in clinical practice. The research in this field is still in its infancy and promises to be exciting in the future. There appears to be a balance of vasomotor tone and cardiac response to meet any emergency and stress such as intermittent dialysis. Further knowledge will increase our chances for major therapeutic interventions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|